Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of Sotorasib With or Without Panitumumab in KRAS p.G12C-Mutated Advanced Solid Tumors
jRCT2011250058Recruiting
- Sponsor
- Amgen
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Open-label trial of sotorasib and panitumumab in Nonhematologic neoplasms (2 arms), sponsored by Amgen. Primary endpoint: Treatment-emergent adverse events. Started Jan 2026; status: recruiting.
02
Drugs
sotorasibpanitumumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2011250058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250058.